环磷腺苷葡胺联合培哚普利在慢性心力衰竭中的应用研究.

Objective: To investigate the application value of meglumine cyclic adenylate and perindopril in patients with chronic congestive heart failure(CCHF) Methods: 90 cases of patients with CCHF in our hospital from January 2013 to December 2015 were divided into control group, perindopril group and union group, 30 cases in each group. Patients in the control group were treated with conventional methods, patients in the perindopril group were treated with conventional methods and perindopril, and patients in the union group were treated with meglumine cyclic adenylate based on the treatment method of perindopril group. The treatment time of three groups were 2 weeks. Compared the clinical effect, LVEDD, LVESD, LVEF, 6-minute walk distance and plasma levels of BNP, IGF-1, Cys-C between three groups. Results: After treatment, the clinical effect of the perindopril group (86.67% )and union group (96.67%) were significantly higher than that of the control group (66.67%)(P<0.05); LVEDD, LVESD, and plasma levels of BNP and Cys-C of three groups after treatment were all significantly lower than before treatment (P>0.05), and the perindopril group and union group were all significantly lower than that of the control group(P<0.05); LVEDD and plasma levels of BNP ofunion group were significantly higher than that of the perindopril group (P<0.05), and the perindopril group were all significantly higher than that of the union group (P<0.05). Conclusion: The clinical effect of meglumine cyclic adenylate and perindopril in patients with CCHF are remarkable, and meglumine cyclic adenylate can improve the effect of perindopril on left ventricular remodeling situation, left ventricular function, and patients' activity, and those may be related with modify the plasma levels of BNP, IGF-1, Cys-C. [ABSTRACT FROM AUTHOR]